Holen Sie sich die Stockscreener-App
253.35
4.20%
10.21
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie (ABBV) Wins Health Canada Approval for Boey - Insider Monkey
AbbVie (NYSE:ABBV) jumps $18 billion Friday, beats Apogee as Skyrizi FDA decision comes Monday - TechStock²
AbbVie (ABBV) to Acquire Apogee Therapeutics - Insider Monkey
SCHULHOFF & CO INC's AbbVie Inc(ABBV) Holding History - GuruFocus
Enterprise value to revenue forward of AbbVie, Inc. CDR (CAD Hedged) – TSX:ABBV - TradingView
Key facts: AbbVie Q2 Jul 31; FDA Approves Skyrizi for 6+ & Ped PsA - TradingView
AbbVie (ABBV) Gains FDA Approval for Skyrizi in Children with Ps - GuruFocus
ABBV Gains FDA Approval for Skyrizi in Pediatric Psoriasis Treat - GuruFocus
AbbVie Inc (ABBV) Stock Up 4.2% but GF Value Says Overvalued -- GF Score: 82/100 - GuruFocus
AbbVie receives FDA approval for Skyrizi in pediatric patients By Investing.com - Investing.com Canada
AbbVie Inc Stock (ABBV) Closed Up by 3.53% on Jun 26: Facts Behind the Movement - TradingKey
Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Bill - Benzinga
Lilly, J&J and AbbVie Hit New Highs - TradingView
why dominant pharmaceutical firms are paying billion dollar premiums for immunology assets - grafa.com
Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms - Seeking Alpha
AbbVie Stock’s Growth Story Has One Question Mark - Trefis
AbbVie stock hits all-time high at 245.26 USD By Investing.com - Investing.com Nigeria
Price to book forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie stock hits all-time high at 245.26 USD - Investing.com
Price to earnings forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie to Host Second-Quarter 2026 Earnings Conference Call - Investing News Network
ABBV Stock Quote Price and Forecast - CNN
Fidelity (FHLC) vs. iShares (IXJ): Which Healthcare ETF Delivers Better Value? - The Motley Fool
Rx Rundown: Merck KGaA, AbbVie, Sangamo Therapeutics and more - Medical Marketing and Media
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $275 - Moomoo
AbbVie, Inc. CDR (CAD Hedged) Actuals & Estimates (FWB:4AB0) - TradingView
AbbVie, Inc. Actuals & Estimates (VIE:ABBV) - TradingView
AbbVie, Inc. CDR (CAD Hedged) Actuals & Estimates (DUS:4AB0) - TradingView
Will AbbVie's (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix? - Yahoo Finance
Enterprise value to EBITDA forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026? - The Motley Fool
A Look at AbbVie Inc (ABBV) After 3.5% Gain -- GF Value $211.36 vs Price $243.14 - GuruFocus
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Price to sales forward of AbbVie, Inc. – TURQUOISE:4ABD - TradingView
Price to book forward of AbbVie, Inc. – TURQUOISE:4ABD - TradingView
Enterprise value to EBIT forward of AbbVie Inc. – NYSE:ABBV - TradingView
AbbVie Inc Stock (ABBV) Moved Up by 3.22% on Jun 25: Drivers Behind the Movement - TradingKey
Is AbbVie a Buy After Its Purchase of Apogee? - AOL.com
AbbVie to acquire Apogee Therapeutics in $10.9 billion immunology deal - DOTmed
Pharma Pulse: UPS's Cold Chain Buildout and AbbVie's $10.9B Immunology Bet - Pharmaceutical Commerce
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook - Yahoo Finance
The Number That Could Test AbbVie Stock - Trefis
AbbVie's Big Immunology Acquisition - Forbes
AbbVie Stock And The Number Behind The Growth Story - Trefis
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years - Benzinga
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis - Zacks Investment Research
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $260 to $298 - Moomoo
AbbVie (ABBV) Stock Draws Fresh Price Target Split After Apogee Deal - Yahoo Finance
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition - Investing.com
Mizuho downgrades Apogee Therapeutics stock on AbbVie acquisition By Investing.com - Investing.com Canada
PRESCRIPTION DRUGS—W.D. Wash.: Novartis, AbbVie, PhRMA denied preliminary relief in challenge to Washington State 340B delivery law - VitalLaw.com
Cash buyout for Apogee (NASDAQ: APGE) at $135.11 a share - Stock Titan
AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors. - Yahoo Finance
ABBV Reiterated by Piper Sandler -- Price Target Maintained at $298 - GuruFocus
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - Benzinga
AbbVie and Galderma Control 80% of Aesthetic Medicine's AI Citations, New 5W Index Finds - PR Newswire
CCORF Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $273 - Moomoo
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout - Yahoo Finance
Abbvie stock holds at Market Perform as Bernstein eyes Apogee deal - Investing.com Canada
ABBV Introduces Boey for Glabellar Lines Following Health Canada Approval - GuruFocus
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $234 to $298 - Moomoo
AbbVie receives European approval for age three patients - grafa.com
Years of Rewards: $61 Bil From AbbVie Stock - Trefis
Canaccord raises Abbvie stock price target on acquisition potential - Investing.com
AbbVie (ABBV) Pursues Acquisition of Apogee Therapeutics - GuruFocus
AbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV) - Yahoo Finance
Canaccord raises Abbvie stock price target on acquisition potential By Investing.com - Investing.com Canada
Should You Buy Or Sell AbbVie Stock At $230? - Yahoo Finance
2.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):